New York Genome Center and Sohn Conference Foundation Collaborate on Pediatric Cancer Research - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

New York Genome Center and Sohn Conference Foundation Collaborate on Pediatric Cancer Research


The New York Genome Center (NYGC) and The Sohn Conference Foundation launched The Sohn Collaborative for Pediatric Cancer Research, a multi-institutional effort with the goal of fighting two childhood cancers: pediatric leukemia and neuroblastoma. NYGC will act as a nexus and participant in this research collaborative with five of its Institutional Founding Members: Columbia University, Memorial Sloan Kettering Cancer Center, New York University School of Medicine, The Rockefeller University, and Weill Cornell Medical College. NYGC will also conduct the genome sequencing and computational analysis for this synergistic research endeavor.

The Sohn Conference Foundation’s grant empowers these institutions to harness their collective knowledge and technology to apply genomic science to identify and analyze why some children’s tumors respond readily to treatment, while other patients suffer relapses or have no response at all. While leukemia and neuroblastoma are different—leukemia affects blood and neuroblastoma is the commonest childhood solid tumor—researchers will pursue a similar approach to understand them. Sequencing the genomes of “outlier” tumors, those that have unusual responses to treatment, either good or bad, may yield valuable clues on how to fight these cancers more effectively

Source: The New York Genome Center

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests

Click here